Basit öğe kaydını göster

dc.contributor.advisorFerman, Ali Muraten_US
dc.contributor.authorTaştekin, Ali Tolgaen_US
dc.contributor.otherIşık Üniversitesi, Sosyal Bilimler Enstitüsü, Yöneticiler İçin İşletme Yönetimi Yüksek Lisans Programıen_US
dc.date.accessioned2016-08-02T13:07:01Z
dc.date.available2016-08-02T13:07:01Z
dc.date.issued2016-06-23
dc.identifier.citationTaştekin, A. T. (2016). An application of niche marketing from Turkish pharmaceutical sector; orphan drugs. İstanbul: Işık Üniversitesi Sosyal Bilimler Enstitüsü.en_US
dc.identifier.urihttps://hdl.handle.net/11729/1068
dc.descriptionText in English ; Abstract: English and Turkishen_US
dc.descriptionIncludes bibliographical references (leaves 126-129)en_US
dc.description140 leavesen_US
dc.description.abstractEnglish; Within this research, with the application of niche marketing to the Turkish pharmaceutical sector the issue of orphan drugs and treatment of rare diseases which are not only Turkey's but also other countries’ problem are evaluated from the marketing point of view. The point which the private and public organizations play crucial role, the aim of this cooperative work is not only to increase its revenue but also its goodwill at pharmaceutical sector. Different areas where public and private organizations work, importance of new product development and R&D, importance of public health, and importance of public education about the usage of appropriate medicine in an appropriate way (rational usage of medicines) are some of the examples. Throughout this research, the subject of orphan medicines and treatment of rare diseases are being evaluated from the perspective of a private pharmaceutical company's niche marketing applications. Within context of this research, the subjects of legislation contents and market dynamics which are assumed to have a direct link to the niche marketing application of orphan medicines and treatment of rare diseases. A course of action and possible research made within the context of niche marketing applications which are believed both to increase the goodwill of the company in the market and to alleviate a public health concern while putting forth improving the health conditions of public with maintaining the financial returns at a sufficient level are emphasized with detailed explanations.en_US
dc.description.abstractTürkçe; Bu araştırmada niş pazarlama uygulamalarının Türk ilaç sektörüne uygulanması ile sadece Türkiye değil ancak diğer ülkelerin yaşadığı en büyük sağlık sorunlarından biri olan yetim ilaç ve nadir görülen hastalıkların tedavisi sorununa pazarlama bakış açısı ile ele alınmıştır. Hem özel sektörün hem de devletin önemli bir rol oynadığı bu noktada, ortak yapılacak araştırmalar ile Türk ilaç sektörü hem gelirini artırması hem de marka değerini yükseltmesi amaçlanmıştır. Devlet ile özel sektörün ortaklaşa çalışacağı farklı alanlar, yeni ürün geliştirme ve AR&GE'nin önemi, halk sağlığının önemi ve halkın doğru ilacı doğru bir biçimde kullanması ile ilgili eğitimler örnek verilen araştırmalardan bazılarıdır. Araştırma boyunca yetim ilaçlar ve nadir hastalıklar konusu özel bir ilaç şirketinin niş pazar uygulamaları bakış açısıyla ele alınmıştır. Araştırmanın kapsamı içerisinde bu alanda yatırım yapmak isteyen bir ilaç firmasının karşılaşabileceği aynı zamanda yetim ilaçlar ve nadir hastalıklar niş pazar uygulamasını doğrudan etkileyebilecek mevzuat içeriği ve pazar dinamikleri de detaylı bir şekilde yer verilmiştir. Firmanın, hem pazarda iyi bilinirliğini artıracak hem de toplumsal bir sağlık sorununa çözüm olacak şekilde, insan sağlının iyileştirilmesini ön plana alırken aynı zamanda finansal geri dönüşünü de yeterli seviyede tutacak bir dizi eylem planı ve muhtemel araştırmalar niş pazarlama kapsamında detaylı anlatımlarla vurgulanmıştır.en_US
dc.description.tableofcontentsINTRODUCTIONen_US
dc.description.tableofcontentsPRINCIPLES OF NICHE MARKETING AND IT’S THEORETICAL FRAMEWORK (ORPHAN DRUGS AND TREATMENT OF RARE DISEASES)en_US
dc.description.tableofcontentsThe Concept of Niche Marketingen_US
dc.description.tableofcontentsDefinition of Niche Marketingen_US
dc.description.tableofcontentsEvolution of Niche Marketingen_US
dc.description.tableofcontentsCircumstantial Requirements for Identification of the Niche Marketsen_US
dc.description.tableofcontentsRelationship Between Market Segmentation and Niche Marketingen_US
dc.description.tableofcontentsRelationship and Database Marketing in Relation with Niche Marketingen_US
dc.description.tableofcontentsRelationship Marketingen_US
dc.description.tableofcontentsDifferent Levels of Relationship Marketingen_US
dc.description.tableofcontentsDatabase Marketingen_US
dc.description.tableofcontentsNiche Marketing Practices at Large Corporationsen_US
dc.description.tableofcontentsComparison of Niche Marketing with Conventional Mass Marketingen_US
dc.description.tableofcontentsProduct Classification and Niche Marketingen_US
dc.description.tableofcontentsFinancial Viability of Niche Marketing (Return on Investment Comparison)en_US
dc.description.tableofcontentsRelationship of Niche Marketing and Product Life Cycle Modelen_US
dc.description.tableofcontentsSelection of Niche Strategiesen_US
dc.description.tableofcontentsPhenomena of Hypernichingen_US
dc.description.tableofcontentsNiche Marketing and It’s Role In Pharmaceutical Sectoren_US
dc.description.tableofcontentsA Detailed Look to the Niche Markets at Pharmaceutical Sectoren_US
dc.description.tableofcontentsBiotechnological Productsen_US
dc.description.tableofcontentsOrphan Drugs / Rare Diseasesen_US
dc.description.tableofcontentsPersonally Customized Pharmaceutical Treatment Products and Methodsen_US
dc.description.tableofcontentsAN EXAMPLE OF NICHE MARKETING APPLICATION IN PHARMACEUTICAL SECTORen_US
dc.description.tableofcontentsOrphan Drugs/ Treatment of Rare Diseases (Access of Government and Patients to Medicines) Supplyen_US
dc.description.tableofcontentsWhat is Orphan Drug?en_US
dc.description.tableofcontentsSupply of Orphan Drugsen_US
dc.description.tableofcontentsBasic Procurement of Orphan Drugsen_US
dc.description.tableofcontentsApplication Principles of Good Procurement of Orphan Drugsen_US
dc.description.tableofcontentsGuide for Orphan Medicine Donationen_US
dc.description.tableofcontentsEmergency Kit for Orphan Medicinesen_US
dc.description.tableofcontentsPublic Awareness About Orphan Drugs and Rare Diseasesen_US
dc.description.tableofcontentsMedicine Information Centersen_US
dc.description.tableofcontentsMedicine Bulletinsen_US
dc.description.tableofcontentsPatient Knowledge and Educationen_US
dc.description.tableofcontentsRational Medicine Usageen_US
dc.description.tableofcontentsMARKET COMPONENTS OF PHARMACEUTICAL INDUSTRYen_US
dc.description.tableofcontentsManufacturersen_US
dc.description.tableofcontentsSituation In Turkey's Domestic Manufacturersen_US
dc.description.tableofcontentsGlobal Manufacturers in Turkeyen_US
dc.description.tableofcontentsPharmaceutical Import Companiesen_US
dc.description.tableofcontentsGovernment Medicines Productionen_US
dc.description.tableofcontentsSGK Pharmaceutical Products and Medical Devices Manufacturing Institutionen_US
dc.description.tableofcontentsMinistry of National Defense Army Pharmaceutical Manufacturing Facilityen_US
dc.description.tableofcontentsPublic Institutions (Public Hospitals and SGK) Procuration Systemen_US
dc.description.tableofcontentsDirect Procurementen_US
dc.description.tableofcontentsStock Management of Public Institutionsen_US
dc.description.tableofcontentsSGK and Third Party Financer Reimbursement Systemsen_US
dc.description.tableofcontentsMain Principles of Reimbursement Systemen_US
dc.description.tableofcontentsCovering the Expenses of the Healthcare Servicesen_US
dc.description.tableofcontentsThird Party Financeren_US
dc.description.tableofcontentsWho are the sides of these financing transactions?en_US
dc.description.tableofcontentsHealth Insuranceen_US
dc.description.tableofcontentsReimbursement Methods at Healthcare Servicesen_US
dc.description.tableofcontentsReimbursement Made on Service Basisen_US
dc.description.tableofcontentsPayments Made Individually in Cashen_US
dc.description.tableofcontentsConventional Retroactive Reimbursement Paymentsen_US
dc.description.tableofcontentsReimbursement Made on Treatment Perioden_US
dc.description.tableofcontentsIndividual Reimbursementen_US
dc.description.tableofcontentsBudgetingen_US
dc.description.tableofcontentsPrudential Reimbursement Methodsen_US
dc.description.tableofcontentsHealthcare Expendituresen_US
dc.description.tableofcontentsReflection of Reimbursement Systems on Pricing (From the Company's Point of View)en_US
dc.description.tableofcontentsRepresentative and Distribution/Sales Medical Warehousesen_US
dc.description.tableofcontentsWhat is the aim of these warehouses in pharmaceutical industry?en_US
dc.description.tableofcontentsRepresentative Medical and Pharmaceutical Warehousesen_US
dc.description.tableofcontentsDistribution/Sales Medical and Pharmaceutical Warehousesen_US
dc.description.tableofcontentsPharmaciesen_US
dc.description.tableofcontentsBehind The Counter Medicines (BTC)en_US
dc.description.tableofcontentsOver the Counter Medicines (OTC)en_US
dc.description.tableofcontentsPrescription Types at Medicines Acquisitionen_US
dc.description.tableofcontentsRed Prescriptionsen_US
dc.description.tableofcontentsGreen Prescriptionsen_US
dc.description.tableofcontentsOrange Prescriptionsen_US
dc.description.tableofcontentsPurple Prescriptionsen_US
dc.description.tableofcontentse - Prescriptions (via MEDULA)en_US
dc.description.tableofcontentsPatients and Their Relativesen_US
dc.description.tableofcontentsFUNDAMENTAL FEATURES OF SERVICES AND PRODUCTS OF PHARMACEUTICAL MARKETen_US
dc.description.tableofcontentsPharmaceuticals are Public Servicesen_US
dc.description.tableofcontentsUncertain Demand of Pharmaceutical Industryen_US
dc.description.tableofcontentsImpossibility of Substitution and Delaysen_US
dc.description.tableofcontentsAimed for the Social Health Purposeen_US
dc.description.tableofcontentsLack of Knowledge of Those Who Demanden_US
dc.description.tableofcontentsMEDICINE AND PHARMACEUTICAL PRODUCT COMPONENTS OF TURKISH PHARMACEUTICAL INDUSTRYen_US
dc.description.tableofcontentsDefinition of Turkish Pharmaceutical Sector and its Developmenten_US
dc.description.tableofcontentsDefinitions of Original and Equivalent Medicinesen_US
dc.description.tableofcontentsOriginal Medicinesen_US
dc.description.tableofcontentsEquivalent Medicinesen_US
dc.description.tableofcontentsInformation About the Market of BTC(Behind the Counter) and OTC(Over the Counter)en_US
dc.description.tableofcontentsTurkish Pharmaceutical Market with Numbersen_US
dc.description.tableofcontentsTurkish Pharmaceutical Market Growth[1]en_US
dc.description.tableofcontentsForeign Trade (Imports vs. Exports)en_US
dc.description.tableofcontentsPricing Systemen_US
dc.description.tableofcontentsWorld Pharmaceutical Manufacturers and Turkeyen_US
dc.description.tableofcontentsPosition of Pharmaceutical Sector in Turkish Economyen_US
dc.description.tableofcontentsAbout Turkish Pharmaceutical Manufacturersen_US
dc.description.tableofcontentsAbout Foreign Pharmaceutical Manufacturersen_US
dc.description.tableofcontentsCloser Look on Major Multinational Players in Turkish Pharmaceutical Marketen_US
dc.description.tableofcontentsAbout Pharmaceutical Imports Made To Turkeyen_US
dc.description.tableofcontentsR&D Structure of Turkish Pharmaceutical Sectoren_US
dc.description.tableofcontentsPatent Protection and Data Exclusivityen_US
dc.description.tableofcontentsPatent Protectionen_US
dc.description.tableofcontentsData Exclusivityen_US
dc.description.tableofcontentsMedicine Licensing Processen_US
dc.description.tableofcontentsTypes of Products Within The Context of Licensing and Pharmaceutical Marketen_US
dc.description.tableofcontentsSteps of Patients Access to Pharmaceutical Products and Healthcare Servicesen_US
dc.description.tableofcontentsManufacture, Marketing, Sales and Distributionen_US
dc.description.tableofcontentsRepresentative and Sales/Distribution Medical Warehousesen_US
dc.description.tableofcontentsPharmaceuticals Reimbursement Systemen_US
dc.description.tableofcontentsMedicine Tracking Systemen_US
dc.description.tableofcontentsNICHE MARKETING STRATEGIESen_US
dc.description.tableofcontentsMarket Challenges and Substitutions of Productsen_US
dc.description.tableofcontentsProfile of Patients and Procurement Approachen_US
dc.description.tableofcontentsSuppliers and Supply Approachen_US
dc.description.tableofcontentsProduct Standards and Their Rangeen_US
dc.description.tableofcontentsAnalysis Methodsen_US
dc.description.tableofcontentsProcess Researchen_US
dc.description.tableofcontentsOrphan Medicines and Treatment of Rare Diseases Niche Marketing From 4P's of Marketing Point of Viewen_US
dc.description.tableofcontentsProducten_US
dc.description.tableofcontentsPriceen_US
dc.description.tableofcontentsPromotionen_US
dc.description.tableofcontentsPlaceen_US
dc.description.tableofcontentsDistinctive Features of Orphan Medicines and Treatment of Rare Diseasesen_US
dc.description.tableofcontentsNiche Marketing Strategic Action Planen_US
dc.description.tableofcontentsCOORDINATION OF PUBLIC INSTITUTIONS TO REACH NICHE MARKETSen_US
dc.description.tableofcontentsMonitoring and Evaluationen_US
dc.description.tableofcontentsMonitoring the National Orphan Drug Policiesen_US
dc.description.tableofcontentsKey Policy Subjectsen_US
dc.description.tableofcontentsChanging Pharmaceutical Sector Dynamicsen_US
dc.description.tableofcontentsGlobalizationen_US
dc.description.tableofcontentsWhat is Voluntary Licensing?en_US
dc.description.tableofcontentsWhat is Compulsory Licensing?en_US
dc.description.tableofcontentsInformation Society and Information Technologyen_US
dc.description.tableofcontentsThe Role of Governmenten_US
dc.description.tableofcontentsGeneration of Government Support at Reaching Niche Marketsen_US
dc.description.tableofcontentsCONCLUSIONen_US
dc.description.tableofcontentsA1 TABLES AND DIAGRAMSen_US
dc.description.tableofcontentsDiagram No.1en_US
dc.description.tableofcontentsReflection of Reimbursements on Pricing[25]en_US
dc.description.tableofcontentsHistorical Development of the Industry [1]en_US
dc.description.tableofcontentsMarket Distributions with Reimbursement Rates of BTC and OTC Medicines [1]en_US
dc.description.tableofcontentsNumber of Companies in Turkish Pharmaceutical Sector[1]en_US
dc.description.tableofcontentsBuilding Blocks of Turkish Pharmaceutical Sector [1]en_US
dc.description.tableofcontentsPricing System of Pharmaceuticals in Turkey[25]en_US
dc.description.tableofcontentsTurkish Pharmaceutical Import List (Most Abundant Ones) [5]en_US
dc.description.tableofcontentsRequirements for Licensing in Generic and Reference Medicines[25]en_US
dc.description.tableofcontentsDiagram No.2 Summary of the Licensing Procedures [25]en_US
dc.description.tableofcontentsPrice Research of Orphan Medicines (PART:1)[13]en_US
dc.description.tableofcontentsPrice Research of Orphan Medicines (PART:2)[13]en_US
dc.description.tableofcontentsPrice Research of Orphan Medicines (PART:3)[13]en_US
dc.description.tableofcontentsMedicines Which Can Treat Different Diseases [8][9]en_US
dc.description.tableofcontentsDiseases Prospective Patient Volumes At Export Markets[8]en_US
dc.language.isoengen_US
dc.publisherIşık Üniversitesien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.lccHD9665.5 T37 2016
dc.subject.lcshDrugs -- Marketing.en_US
dc.subject.lcshDrugs -- Research -- Economic aspects -- Turkey.en_US
dc.subject.lcshPharmaceutical industry -- Turkey.en_US
dc.subject.lcshPharmaceutical industry -- Research -- Turkey.en_US
dc.subject.lcshOrphan drugs -- Goverment policy -- Turkey.en_US
dc.subject.lcshPharmaceutical industry -- Marketing.en_US
dc.titleAn application of niche marketing from Turkish pharmaceutical sector; orphan drugsen_US
dc.title.alternativeTürk ilaç sektöründen bir niş pazarlama uygulaması; yetim ilaçlaren_US
dc.typemasterThesisen_US
dc.contributor.departmentIşık Üniversitesi, Sosyal Bilimler Enstitüsü, Yöneticiler İçin İşletme Yönetimi Yüksek Lisans Programıen_US
dc.relation.publicationcategoryTezen_US
dc.contributor.institutionauthorTaştekin, Ali Tolgaen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess